An Investigation of the Effect of Exchange Rate on the Pharmaceutical Industry Stock Return in Tehran Stock Exchange: An Application of the Markov Switching Approach

• Main Authors: Hasan Heidari, Yousef Mohammadzadeh, Arash Refah-Kahriz
• Format: Article
• Language: fas
• Published: University of Isfahan 2018-06-01
• Series: Journal of Asset Management and Financing
• Subjects: stock market; sustainability; pharmaceutical industry; markov switching model; exchange rate
• Online Access: https://amf.ui.ac.ir/article_21420_41711cd1344a9e1a17871a7f868ca83a.pdf

Nowadays, the pharmaceutical industry in terms of its relationship with public health and also the special economic value is considered one of the most important industries in the capital market. Therefore, improvement of the health sector has always been the main objective of the authorities in various countries. Hence, this paper investigates the impact of exchange rate on the pharmaceutical industry stock return in Tehran Stock Exchange by using monthly data from 2005:4 to 2016:2 and applying Markov switching non-linear approach. For this purpose, among the various modes of Markov switching model, MSIH (3) -AR (2) has been selected. The results show that in an optimal model consists of three regimes, and the exchange rate has different impact on the return of the pharmaceutical industry in different regimes. As a result; coefficients exchange rate in the first regime has negative effect, but in regimes 2 and 3 positive effect on the pharmaceutical industry stock return in the Tehran Stock Exchange. Also, the inflation rate of the health sector in the regimes 1 and 2 have a positive effect, but in the regime 3 has a negative effect on the pharmaceutical industry stock return in Tehran Stock Exchange. In addition, the results show that the sustainability of the pharmaceutical industry return in the regime with the high returns (first regime) was more than that of the regime with the little low return (second regime) and that of the regime with the high low returns (third regime). But the volatility of the pharmaceutical industry return in the third regime was more than that of the first and second regimes.